Emergent BioSolutions
EBS
#6745
Rank
HK$5.00 B
Marketcap
HK$93.81
Share price
3.88%
Change (1 day)
27.79%
Change (1 year)

Emergent BioSolutions (EBS) - Cash on Hand

Cash on Hand as of September 2025 : HK$1.91 Billion

According to Emergent BioSolutions 's latest financial reports the company has HK$1.91 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Emergent BioSolutions - Cash on Hand chart (from 2004 to 2025)

Cash on Hand by year

Year Cash on Hand Change
2024-12-31HK$0.77 B-11.45%
2023-12-31HK$0.87 B-82.62%
2022-12-31HK$5.02 B11.77%
2021-12-31HK$4.49 B-6.73%
2020-12-31HK$4.81 B268.55%
2019-12-31HK$1.30 B48.74%
2018-12-31HK$0.87 B-36.93%
2017-12-31HK$1.39 B-33.84%
2016-12-31HK$2.10 B-11.89%
2015-12-31HK$2.38 B9.83%
2014-12-31HK$2.17 B56.45%
2013-12-31HK$1.39 B26.64%
2012-12-31HK$1.09 B-3.08%
2011-12-31HK$1.13 B-14.89%
2010-12-31HK$1.33 B66.8%
2009-12-31HK$0.79 B12.9%
2008-12-31HK$0.70 B-14.26%
2007-12-31HK$0.82 B38.7%
2006-12-31HK$0.59 B111.21%
2005-12-31HK$0.28 B430.87%
2004-12-31HK$53 M
2002-12-31HK$38.14 M-16.44%
2001-12-31HK$45.64 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
Merck
MRK
HK$141.79 B 7,319.14%๐Ÿ‡บ๐Ÿ‡ธ USA
SIGA Technologies
SIGA
HK$1.33 B-29.96%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
HK$34.59 B 1,710.34%๐Ÿ‡ฌ๐Ÿ‡ง UK
Celldex Therapeutics
CLDX
HK$4.54 B 137.57%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
HK$116.64 B 6,003.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
HK$17.14 B 797.35%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Soligenix
SNGX
HK$81.93 M-95.71%๐Ÿ‡บ๐Ÿ‡ธ USA